Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice

Lignende værker

• Intervention with a caspase-1 inhibitor reduces obesity-associated hyperinsulinemia, non-alcoholic steatohepatitis and hepatic fibrosis in LDLR−/−.Leiden mice
  af: Morrison, M C, et al.
  Udgivet: (2016)
• Key Inflammatory Processes in Human NASH Are Reflected in Ldlr(−/−).Leiden Mice: A Translational Gene Profiling Study
  af: Morrison, Martine C., et al.
  Udgivet: (2018)
• A casein hydrolysate based formulation attenuates obesity and associated non-alcoholic fatty liver disease and atherosclerosis in LDLr-/-.Leiden mice.
  af: Marieke H Schoemaker, et al.
  Udgivet: (2017-01-01)
• A casein hydrolysate based formulation attenuates obesity and associated non-alcoholic fatty liver disease and atherosclerosis in LDLr-/-.Leiden mice
  af: Schoemaker, Marieke H., et al.
  Udgivet: (2017)
• Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial
  af: Tiessen, Renger G., et al.
  Udgivet: (2018)